Orchid Pharma Limited

Regd.

Ph. +91

-

44

- 2621

Statement

Office:

"Orchid Towers'

2313,

Valvar Koltak

High Road, Nungambakkam, Chennai -

£00034, Tami! Nadu, India

1000

/ 2823

0000 Fax;

+91-44- 28211002

Email

id: corporate@orchidpharma.com

'Website: www.archidphermacom

CIN 1 L24222TN1992PLC022994

of audited

Standalone

and

Consolidated

Finan,

| Results for the quarter and

year

ended March 31, 2023

{All

amounls

are in lakhs

of

Indian Rupees,

unless

otherwise

stated)

5.Ne.

|Particulars

Standalone financial

results

Consclidated

financial

results

For

the

For

the

Fer

the

For

the

guarter énded

year

ended

quarter

ended

year

ended

9

Mar

31, 2023

Dec

31,2022

|

Mar31,2022

|

Mar

31,2023

|

Mar 31,2022

| Mar34,2023

| Dec 31,2022 |

Mar31,2022

| Mar34,2023

| Mar

31, 2022

(Audited)

(Unaudited)

(Audited)

(Audited)

{Audited)

(Audited)

{Unauditad}

{Audited)

(Audited)

{Audited}

{Refer Note 6}

{Refer Nota 6}

(Refer Note 6)

{Refer

Note 6)

Income from

Cantinuing Operations

1

[Net Sales / Income from operations

20,930.68

15.976.03

18,023.41

66,585.84

£5,63744

20,930.08

15,976.03

1781323

66,589.84

55,955.74

2

|Other

fncome

4

172.87

863.10

174.69

1,943.05

900.2%

172.87

833.10

174.69

1,243.05

900.29

3

|Tetal

Income

(142)

21,162.95

15,869.13

18,198.10

£8.532.89

£6,597.73

21,162.95

16,869.43

17,987.92

68,532.89

56,856.03

  • |Expenses

Cost

of

materials

consumed

10,421.63

7,675.36

9,868.62

40,609.61

33,679.89

10,421.63

7,675.36

9880.82

40,609.61

34.06.77

Changes

In

inventories

of raw

material, work-in-prograss,

stack-n-trade

1,488.59

1,884.69

317.09

(2,147.54)

(2,272.56)

1,468.59

1,884.69

317.09

(2,147.54)

(2,705.83)

and finished

goods

-

Employee

benefit

expenses

1,636.13

1,667.74

1,377.02

8,535.04

6,020.60

1,636.13

1,667.71

1398.03

6,535.04

6,327.70

Finance

costs

748.38

766.03

44587

3.22257

320147

748.38

768,03

445.87

322257

[3201.47

Dep/aciation

and

amorfizalion

expense

72121

816.13

2,862.73

5478.58

8,702.08

221

818.13

2662.03

5,478.68

8,702.46

Other

expenses

3404.88

338237

351291

13,230.88

12,543.58

494.97

3,382.37

3640.68

13,230.68

12.956.63

Total

Expenses

18,490.92

16,196.29

18,184.24

£6,929,24

61,874.77

18.490.91

16,196.29

18,344.52

66,929.24

§2,545.30

§

|Prafit!

{Loss)

before

exceptional

items and tax {3-4)

2,672.03

£72.84

13.85

1,603.65

(5,277.04)

2,672.04

672.84

{356.60)

1,603.65

(5,689.87)

6

[Exceptional

ilems

[Refer Mote

No.

4)

3921.04

-

-

3821.04

-

1,921.04

-

3921.04

=

7

|Profit/

{Loss}

before

tax {rom continulng operations

{5+5)

6,593.07

672.84

13.86

5524.69

(5,277.04)

6,593.08

572.34

(356.60)

5,524.89

(5,689.87)

  • |Taxexpense

Current

tax

-

-

-

-

-

-

-

5

%

Deferred

tax

-

-

-

-

-

-

.

.

Tolal Tax

Expenses

-

-

=

2

a

.

9

Profit! {L oss)

for the period from continuing operations (7-8)

8,593.07

672.84

6,593.08

£72.84

(356.50)

5524.69

(5,689.87)

18

19

19

18

17

.

.

.

3

2

1

_

-

-

operations)":

|Earnings

-

-

-

"

[Earnings

-

(Earnings

Face |Paid

[Total

Basic

Total

EPS

Ditted

Diluted

Basic

Diluted

Basic

-

lor

value

up

comprehensive

other

the

(Rs)

{Rs)

per

(Rs)

per

{Rs

(Rs)

per

equity

{Rs)

per

comprehensive

quarters

.

equity

)

equity

share

share

equity

capital

are

share

share

share

(Rs)

income!

nol

(

{

annualised

For

For

income!

{Loss

{

For

discontinued

continuing

discontinued

for

floss),

the

operations

operations)

period

net

of

income

&

{15416}

*;

continuing

}*

tax

;

14 13 12 11 10

[5

18 15

9

No,

to

{ii}

(7)

{i} {il

[Other

Profit]

|Add:

|Profitf

|Profit!

[Profit

[Profit]

}

a]

[Tax

[Particulars

profit

income

income

Share

items

reclassified

lems

comprehensive

(Loss)

(Loss)

(Loss)

expense

{Loss)

or

tax

thal

lax

that

of

of {Loss}

be

not

the

Profit!

for

the

loss

refating

wi

lo

relating

wit

for

from

discontinued

from

for

profit

period

(Loss)

peried

reclassified

the

discontinued

disconfinued

from

before

v

items

loss

tems

be

income,

of

period

to

or to

reclassified

or

thal

of

{13+14)

Associates

of

operations

that

not

net

10

share

operations

aperations

continuing

will

profil

will

income

be profit

to

be

reclassified

loss

of

tax

profit

(after

loss

of

operations

Assotfates

tax)

-

{1011}

8)

(7

($412)

Statement

of audited Standalone and Consolidated Financial Results for the

Orchid

Pharma

Limited

15

15

{0

16

16

10

8,572

91

.. . . .

4,081 .

89

69

26) 0:25)

15 15

. .

17

.

00]

54

51

1

1

10

636

36

.

B - .

4,081 . .

185 85

65 165 .

.

25

59)

64

00

(0

(0

(0

{0

0 0

83

94

.. . .

. .

10

4,001 .

44) 44)

47) 47)

70)

.

03

03

. .

41

00 5¢

12

13

0

13

13

5401

{17

..

{0 .

10

2828

.

. .

4,081 . .

28) 26)

54 54

. .

00

88)

00 64

(1

(1

1

11

(12

(12

338

142

.

10

..

. . .

4,081 . .

18)

18)

75 75

33)

93)

. .

42)

30

001

64

1414

£1 (1

16

18

10

6,005

81

..

4949

. . . .

4,081 . .

66) 68)

15 15

. .

88

91

00 64

.

11

1

1

10

4081

722

(36

..

. =

8686

. .

.

.

86

85

. .

40

00 84

59)

(1(1

0

(0

(1

(1

4081

(564

94

..

.

61)61)

47)

. . .

10 . . .

47)

14)

14)

.

64

23)

41

00

1111

(1

{1

13

13

4,613

(17

..

10

3535

. . . .

4,031 .

66) 65}

01 04

. .

95

.

00 64

88)

(0(0

14 14

(14

{14

10

{52

142

.

. . . .

.

48)48)

32 32

80)

4,081 . .

80)

. .

82)

30

|

00

64

= -

=

HNN

136

  • - - . 59)

94 u - . 41

oe

{17 . 88)

142 . 30

91

L - . . 91

  • {36
    • . .
      59

94

=

. .

41

(17

.

88)

142

R

=

z .

33

5,487

6,487

{10581)

(105

£,593,07

. . .

81)

- .

26

25

672 .

672

72

.

-

84

- .

84

-

84

178

{178

(121

(191

13,26

.

11)

41)

87)

97)

. . .

- .

5,418

5,413

(105

(105

5,524

. . .

. - . .

88

88

81)

81)

69

(480

(480

4

4,756

(5,277

.

.

- .

79532

32

. . .

72)

72)

04)

591387

(1

5,915

(677

(677

6,593

.

.

.

- . .

60)

57

51)

51)

08

758

85

672

£72

. .

.

- - - .

59

85

84

84

(658

{110

(549

{191

{191

{356

. .

.

. - . .

84)

07}

57)

97)

37}

50}

4631

(215

4,347

(877

(877

5,524

.

83

. . . . .

35)

18

51)

51)

69

[185

{352

157

5547

5,847

(5,689

.

.

. .

- . .

12)

15 02

27

02

87)

(Refer

(Audited)

Mar

Mote

31,

§)

2023

{Unaudited]

Dec

quarter Fer

31,2022

ended

the

Stand

(Refer

(Audited)

Mar

alone

financial

Note

2022

31,

6)

(Audited)

Mar

results

For

37,2023

the

|

year

(Audited)

Mar

ended

34,2022

|

{Rees

{Audiled)

Mar

Hole

31,2023

6}

|

quarter For

Unaudited)

Dec

31,2022

ended

the

Consolidated

{Refer

|

Note {Audited}

Mar

31,2022

financial

6)

(Audited)

Mar

results

31,2023

the

For

|

year

(Audited)

Mar

ended

31,

2022

quarter and year ended March 31,2023

(Contd ... )

TOTAL

Tolal

Current

Other

LoansBank

Cash

Trade

ASSETS

current

Olher

Non

Investments

assels

current

current

lax

financial

balances

and

receivables

assels

assets

assets

cash

held

{net)

assets

other

equivalents

for

than

safe

above

and

disposal

groups

1,22,325

49,379

2,515

95

458402

1,830

21,180

.

.

0

719

38

.

.

37]

.

....

85

-

7281)

7773

13

-

1,09418

38,307

323735

1,328

31

0

375

45,02

16,022

95

24

97

78

14

64

73

-

..

....

.

|

|

1,22,52063|

97

96

-

837734

-1

71

38

-

50,100

2,533

15

802

2588

21,519

. .

2,

.

....

1,11,086

39,764

3,275

1,328

31

0

375

430

17,056

.........

25

95

33

97

76

44

-

64

66

62

.

Current

Total

Finantial

Inventories

assets

non

Financial

Intangible

Capital

Intangitle

Property,

current

non

current

Ciher

-

work

-

Other

Mon

vestments

assets

assets

currenl

tax

financial

assels

Assets

in

assets

plant

assets

progress

and

assels

assels

under

equipment

{net)

Development

L

22,873

72,946

202

5130

587

5011

4609

3B

57,267

.

..

...

.

..

154885

-18

80

41

1

57

07

17,265

71,111

1,166

5,223

4,901

978

$8,331

.

476.

3373

63

71

84

83]

05

35

-42)

59)

.

...

..

22,873

72,415

202

5130

587

4444

4,646

38

57,270

.

80

.

....

..

.

11

154813

88

66

-34

57

17,265

71,291

1,693

52253

475

4,549

478

58,336

.

ExNK!

30

34

05 08

42

55

63

....

..

-

Non

ASSETS

Particulars

current

-

3

assets

(Audited)

3,

AsatMarch

2023

Standalone

|

(Audited)

31,2022

AsatMarch

(Audited)

|

2023

AsatMareh

31,

Consolidated

3,

|

(Audited)

As

March

at

{in

2022

lakhs)

|

Statement of assels and fabilities

StatementofauditedStandaloneandConsolidatedFinancialRastiltsforthequarterandyearendedMareh31,2023(Contd...)

UTCNIa Fnarma umited

TOTAL

Total

Current

Total

Non

Lizbilitfes

Total

Equity

EQUITY

ParticularsStatement

Liabilities

non

Other

Sheri

Financial

DeferredProvisions

-

equity

Other

Equily

EQUITY

Trade

Bofiowings

-

Borrowings

Financialcurrent

AND

current

term

Habilities

equity

share

assets

AND

current

Tax

liabilities

provisions

fiabilities

Liabfity

liabilities

capital

LIABILITIES

of

&

LIABILITIES

payables

iabfifies

fabiities

llabilifles

and

(Net)

(Contd

..

)

:

1,22,325

{Audited}

31,2023

As

48,129

32,862

411

348

13,662

18,250

16,466

..

73,186

.

4,081

.

.

.

....

.

79

53

97

26

60

30

81

56

32262

18

78

.

.

atMarch

Standalone

26

6264

2224043

32262

|

95

68

26

98

71

73

.

AsatMarch

109,418

.

.

....

1,104.

795

63,713

4,081

{Audited)

31,2022

.

41,623

19,383

1,029

300

12,073

5,978

20,816

£7

.

84

.

52

.

.

29

26

62

64

|

3228218

|

63

73

17

26

80

50

81

56

76

90

2664

AsatMarch

1,22

{Audited)

31,2023

....

.

. .

.

. .

.

.

.

16,466

1,260

14,883

68,864

64,783

4,081

520

53,655

37,189

411

343

18,178

18,250

Consolidated

|

1,11,056

(Audited)

31,2022

As

46,318

24,077

1,029

300

16,758

5,978

22,240

32262.

.

..

March

25

26

83

98

71

50

84

43

.

.

.

.

.

.

. .

.

1,101

54,737

60,656

4,081

20,816

al

{In

2952

99

35

64

lakhs)

Statement

Orchid

of audited

Pharma

Standalone

Limited

and

Consolidated

Financial

Results

for the

and yearquarterended

March

31, 2023

(Contd...)

Attachments

Disclaimer

Orchid Pharma Ltd. published this content on 11 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 May 2023 12:30:03 UTC.